Three drug companies are racing to bring to market a new cholesterol-lowering medication that reproduces the effects of a genetic mutation that causes extremely low LDL levels. Preliminary studies indicate the drugs are capable of reducing persistently high LDL levels to 50 or lower, leading some researchers to question whether cholesterol can be too low. Studies underway will attempt to answer some of the core public health questions, including whether the drugs can cut heart attacks and cardiovascular deaths.
Is the next cardiovascular blockbuster on the horizon?
SmartBrief Job Listings for Health Care
|Director, Senior Legal Counsel||
|Fort Worth, TX|
|Senior Scientist - Cell Engineering Group||
|San Francisco, CA|
|Associate Director, Compliance Business Partner I||
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
|Silver Spring, MD, MD|
|Counsel – Regulatory Affairs||
RAI Services Company
|Winston Salem, NC|